HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mariola Fotin-Mleczek Selected Research

Antigens

5/2019A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
1/2019Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
1/2017Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.
1/2016Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
7/2015A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
1/2015Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
10/2014Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
6/2012Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
1/2011Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mariola Fotin-Mleczek Research Topics

Disease

11Neoplasms (Cancer)
05/2019 - 01/2011
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2019 - 06/2012
4Human Influenza (Influenza)
01/2017 - 10/2013
2Communicable Diseases (Infectious Diseases)
10/2019 - 01/2017
2Virus Diseases (Viral Diseases)
10/2017 - 01/2017
2Rabies (Hydrophobia)
10/2017 - 01/2017
2Prostatic Neoplasms (Prostate Cancer)
01/2015 - 06/2012
1Severe Acute Respiratory Syndrome
04/2021
1COVID-19
04/2021
1Melanoma (Melanoma, Malignant)
05/2019
1Thymoma (Thymic Carcinoma)
04/2018
1Infections
10/2017
1Uterine Cervical Neoplasms (Cancer of the Cervix)
07/2015
1Disease Progression
10/2014
1Lung Neoplasms (Lung Cancer)
08/2014
1Septic Shock (Toxic Shock Syndrome)
02/2006
1Sepsis (Septicemia)
02/2006
1Necrosis
08/2005

Drug/Important Bio-Agent (IBA)

14Messenger RNA (mRNA)IBA
04/2021 - 01/2011
9AntigensIBA
05/2019 - 01/2011
6VaccinesIBA
01/2017 - 10/2013
5mRNA VaccinesIBA
04/2021 - 01/2011
2Proteins (Proteins, Gene)FDA Link
04/2021 - 07/2015
2Lipid NanoparticlesIBA
04/2021 - 10/2017
2SurvivinIBA
05/2019 - 01/2019
2Peptides (Polypeptides)IBA
07/2015 - 08/2005
2Cancer VaccinesIBA
10/2014 - 08/2014
1AntitoxinsIBA
10/2019
1Glycoproteins (Glycoprotein)IBA
05/2019
1Protamines (Protamine Sulfate)FDA Link
01/2019
1OvalbuminIBA
04/2018
1CytokinesIBA
04/2018
1AntibodiesIBA
10/2017
1vesicular stomatitis virus G proteinIBA
01/2017
1Immunoglobulin G (IgG)IBA
01/2017
1Hemagglutinins (Hemagglutinin)IBA
01/2017
1Subunit VaccinesIBA
01/2017
1Poly I-CIBA
07/2015
1Neoplasm Antigens (Tumor Antigens)IBA
06/2012
1DNA (Deoxyribonucleic Acid)IBA
07/2011
1LipopolysaccharidesIBA
02/2006
1Arginine (L-Arginine)FDA Link
08/2005

Therapy/Procedure

8Immunotherapy
05/2019 - 01/2011
4Therapeutics
10/2019 - 07/2011
4Radiotherapy
01/2019 - 08/2014
1Radioimmunotherapy
04/2018
1Injections
10/2017
1Castration
01/2015
1Drug Therapy (Chemotherapy)
06/2012